IVIS Lumina LT In Vivo Imaging System

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Australia

Austria

Belgium

Brazil *

Canada

China *

Denmark

Finland

France

Germany

Hong Kong *

India *

Ireland

Italy

Japan *

Luxembourg

Mexico *

Netherlands

Norway

Philippines *

Republic of Korea *

Singapore *

Spain

Sweden

Switzerland

Thailand *

United Kingdom

United States

IVIS Lumina LT In Vivo Imaging System

The IVIS® Lumina LT Series III pre-clinical in vivo imaging system offers the industries most sensitive benchtop platform at an entry level price.

For research use only. Not for use in diagnostic procedures.

View product information View Optical Imaging Reagents

Product Variant

Imaging Modality: 2D Bioluminescence, 2D Fluorescence

Part #:

CLS136331

Request a Quote Request More Information

View Optical Imaging Reagents

Product information

Overview

The standard instrument is equipped with full bioluminscence, radioisoptic (Cerenkov) imaging capabilities for 2D imaging and standard fluorescence. For more sophisticated fluorescent models, the Lumina LT can be upgraded to a full Lumina Series III.

Features/Benefits:

Bioluminescence
Fluorescence
Radioisotopic Cerenkov Imaging
Compute Pure Spectrum Spectral Unmixing
DyCE Imaging (Optional Upgrade)
Extended NIR Range 150W Tungsten EKE
Absolute Calibration to NIST® Standards
Complimentary Living Image™ software licenses are provided with the IVIS systems and upon request.

Specifications

Physical Specifications

Height	104.0 cm
Width	48.0 cm

Other Specifications

Brand	IVIS
Imaging Modality	2D Bioluminescence 2D Fluorescence
Unit Size	1 Unit

References

Wang et al (2021). LncRNA SPOCD1-AS from ovarian cancer extracellular vesicles remodels mesothelial cells to promote peritoneal metastasis via interacting with G3BP1. J Exp & Clin Res. 40(101). https://doi.org/10.1186/s13046-021-01899-6
Zhong et al (2021). Calcium phosphate engineered photosynthetic microalgae to combat hypoxic-tumor by in-situ modulating hypoxia and cascade radio-phototherapy. Thernostics. 11(8): 3580–3594. https://dx.doi.org/10.7150%2Fthno.55441
Li et al (2020). High selective distinguishable detection GSH and H2S based on steric configuration of molecular in Vivo. Dyes & Pigments. 172;107826. https://doi.org/10.1016/j.dyepig.2019.107826
Korolev et al (2020). Fluorescent Nanoagents for Biomedical Applications. Fluorescence Methods for Investigation of Living Cells and Microorganisms. https://doi.org/10.5772/intechopen.92904
Zhai et al (2020). An ATF24 peptide-functionalized β-elemene-nanostructured lipid carrier combined with cisplatin for bladder cancer treatment. Cancer Biol & Med. 17(3): 676–692. https://dx.doi.org/10.20892%2Fj.issn.2095-3941.2020.0454
Natoni et al (2020). Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. Haematologia. 105(2): 457–467. https://dx.doi.org/10.3324%2Fhaematol.2018.212266
Costa et al (2019). Murine infection with bioluminescent Leishmania infantum axenic amastigotes applied to drug discovery. Sci Reports. 9: 18989. https://doi.org/10.1038/s41598-019-55474-3
Ramachandran et al (2019). Non-invasive in vivo imaging of fluorescence-labeled bacterial distributions in aquatic species. Internat'l J Vet Sci Med. 5(2). https://doi.org/10.1016/j.ijvsm.2017.09.003
Song et al (2019). Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging. Nanothernostics. 3(2): 223–235. https://dx.doi.org/10.7150%2Fntno.35935
Lorscheider et al (2019). Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. J Controlled Rel. 296:179-189. https://doi.org/10.1016/j.jconrel.2019.01.015
Lazzari et al (2018). Multicellular spheroid based on a triple co-culture: A novel 3D model to mimic pancreatic tumor complexity. Acta Biomaterials. 78: 296-307. https://doi.org/10.1016/j.actbio.2018.08.008
Cayre et al (2017). In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squalene‐Based Prodrug Nanoparticles. Adv. Healthcare Mat. https://doi.org/10.1002/adhm.201700830